Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYLTEZO vs DOXAZOSIN MESYLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
Rheumatoid arthritis (moderate to severe active disease),Juvenile idiopathic arthritis (polyarticular, 2 years and older),Psoriatic arthritis,Ankylosing spondylitis,Adult Crohn's disease (moderate to severe, anti-TNF naïve),Ulcerative colitis (moderate to severe in adults),Plaque psoriasis (moderate to severe chronic, adult),Hidradenitis suppurativa (moderate to severe, adult),Uveitis (non-infectious intermediate, posterior, and panuveitis in adults and pediatrics)
Hypertension,Benign prostatic hyperplasia (BPH),Off-label: Pheochromocytoma (preoperative management), Raynaud's phenomenon, ureteral stones
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
Adalimumab is a monoclonal antibody; it is degraded by proteolytic enzymes into small peptides and amino acids. No specific metabolic pathways or CYP450 enzymes involved.
Extensively metabolized in the liver via O-demethylation and hydroxylation, primarily by CYP3A4.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
Adalimumab binds specifically to soluble and membrane-bound TNF-alpha; does not bind to other serum proteins; binding to specific target is high affinity but no general protein binding data reported.
Approximately 98-99% bound to plasma proteins, primarily albumin.
Approximately 4.7–6.0 L (0.07–0.09 L/kg for a 70 kg adult); indicates distribution primarily within the vascular and interstitial spaces.
0.5-1.5 L/kg, indicating extensive distribution into tissues and extravascular spaces.
Subcutaneous: 64% (absolute bioavailability).
Oral bioavailability is approximately 65% due to first-pass metabolism. Food does not significantly affect absorption.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment.
No dose adjustment needed for renal impairment. Doxazosin is minimally renally excreted.
No dose adjustment recommended. Not studied in patients with hepatic impairment.
Contraindicated in severe hepatic impairment (Child-Pugh C). In mild-moderate impairment (Child-Pugh A or B), use with caution; consider starting at 1 mg once daily and titrate slowly.
For juvenile idiopathic arthritis (2 years and older): 10-30 mg subcutaneously every other week (10 mg if <15 kg, 20 mg if 15-30 kg, 40 mg if ≥30 kg). For pediatric plaque psoriasis (4 years and older): weight-based dosing with maximum 40 mg starting dose, then 0.8 mg/kg up to 40 mg every other week. For pediatric hidradenitis suppurativa (12 years and older): 40 mg every other week.
Safety and effectiveness in pediatric patients have not been established. Not recommended for use in children.
No specific dose adjustment. Use with caution due to increased risk of infections. Monitor renal and hepatic function.
Use cautiously due to increased risk of orthostatic hypotension, dizziness, and falls. Start at 1 mg once daily, titrate slowly. Monitor blood pressure carefully.
Serious infections: Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to opportunistic pathogens. Discontinue if serious infection develops. Test for latent TB prior to initiation; treat latent TB before use. Lymphoma and other malignancies: Malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers, including adalimumab. Hepatosplenic T-cell lymphoma (HSTCL) has occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers.
None
Serious infections (including TB, invasive fungal infections, and other opportunistic infections),Malignancies (including lymphoma and HSTCL),Hepatitis B reactivation in chronic carriers,Demyelinating disease (new onset or exacerbation),Cytopenias (including pancytopenia and aplastic anemia),Congestive heart failure (worsening or new onset),Lupus-like syndrome,Serious allergic reactions (including anaphylaxis),Immunizations: Avoid live vaccines during therapy
Orthostatic hypotension and syncope, especially with first dose ('first-dose effect'),Risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery,Hepatic impairment may decrease metabolism,Priapism (rare),Drowsiness/somnolence, caution with operating machinery
Severe infection (e.g., sepsis, active TB),Moderate to severe heart failure (NYHA class III/IV) - relative,Known hypersensitivity to adalimumab or any component
Hypersensitivity to doxazosin or quinazolines,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension,Severe hepatic impairment
No significant food interactions reported. Avoid alcohol if liver function is compromised.
Avoid grapefruit and grapefruit juice as they may increase drug levels. No other significant food interactions.
CYLTEZO (adalimumab-adaz) is a TNF-alpha inhibitor. Human data on teratogenicity are limited; however, large cohort studies do not indicate a significant increase in major birth defects. Theoretical risk of harm to the fetus due to TNF inhibition; however, placental transfer is minimal during first trimester but increases in second and third trimester. There is evidence of increased risk of infections in neonates exposed in utero during later pregnancy. Therefore, use is not recommended in the third trimester unless clearly needed.
FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and well-controlled studies in pregnant women. Potential fetal risks include possible hypotension and reduced placental perfusion, especially in the second and third trimesters. Use only if potential benefit justifies risk.
Adalimumab is excreted in human milk in low amounts; M/P ratio not established for adalimumab-adaz specifically. The molecular weight suggests it is unlikely to be absorbed by the infant in significant amounts. Expert consensus generally considers TNF-alpha inhibitors compatible with breastfeeding, but caution is advised. Monitor infant for potential adverse effects such as increased risk of infections or hypersensitivity.
Doxazosin is excreted in human milk. The milk-to-plasma ratio is not reported. Caution is advised; monitor infant for signs of hypotension. Consider alternative therapy in hypertensive mothers during breastfeeding.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, potentially requiring dose adjustments. However, there is insufficient evidence to recommend specific dose changes. Generally, continue same dose if benefit outweighs risk, but consider discontinuing in the third trimester to minimize fetal exposure, with dose adjustments as needed postpartum.
No specific dose adjustments recommended for pregnancy. However, consider increased clearance and volume of distribution, especially in third trimester. Start with lowest effective dose (1 mg/day) and titrate based on blood pressure response. May require more frequent monitoring.
CYLTEZO (adalimumab-adbm) is a TNF-alpha inhibitor biosimilar to Humira. Subcutaneous injection sites should be rotated; do not inject into tender, bruised, or scarred skin. Live vaccines are contraindicated during therapy. Screen for latent TB and hepatitis B prior to initiation. Monitor for signs of infection, especially in elderly patients. Consider temporary discontinuation if serious infection occurs. May increase risk of lymphoma and other malignancies. Not recommended in patients with moderate to severe heart failure.
First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly based on standing blood pressure. Monitor for orthostatic hypotension, especially in elderly. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery. Also used for benign prostatic hyperplasia (BPH) and hypertension.
Cyltezo is a biosimilar of Humira and works by reducing inflammation.,Inject the medication subcutaneously as directed; rotate injection sites.,Do not receive live vaccines (e.g., MMR, chickenpox, nasal flu) while on Cyltezo.,Contact your doctor immediately if you have signs of infection (fever, cough, painful urination).,Seek medical attention for symptoms of allergic reaction (hives, difficulty breathing, swelling).,Inform your doctor if you have a history of TB, hepatitis B, heart failure, or cancer.,Store Cyltezo in the refrigerator; do not freeze. Protect from light.
Take the first dose at bedtime to minimize dizziness.,Avoid sudden standing; rise slowly from sitting or lying positions.,May cause drowsiness; do not drive until you know how the medication affects you.,Avoid alcohol, as it can increase dizziness and drowsiness.,Inform your surgeon if you are taking this drug before cataract surgery.,Do not skip doses or discontinue abruptly; consult your doctor.
No interactions on record
"Rifampicin is a potent inducer of cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of doxazosin. Concurrent use significantly increases doxazosin clearance, reducing its plasma concentration and thereby diminishing its antihypertensive effect. This interaction may lead to loss of blood pressure control, necessitating dose adjustment or alternative therapy."
"Clemastine, a first-generation antihistamine, is primarily metabolized by hepatic cytochrome P450 enzymes, including CYP2D6 and CYP3A4. Doxazosin, an alpha-1 adrenergic receptor antagonist used for hypertension and benign prostatic hyperplasia, can inhibit these CYP isoenzymes, potentially leading to reduced clemastine clearance and elevated plasma concentrations. This may increase the risk of clemastine-related adverse effects such as sedation, anticholinergic toxicity (e.g., dry mouth, urinary retention), and paradoxical CNS stimulation, especially in elderly or renally impaired patients."
"Doxazosin, an alpha-1 adrenergic receptor antagonist, blocks vasoconstriction mediated by catecholamines, thereby opposing the vasopressor effects of ritodrine, a beta-2 adrenergic agonist that also possesses alpha-adrenergic activity. This pharmacodynamic antagonism can reduce the efficacy of ritodrine in achieving uterine relaxation and may lead to inadequate tocolysis or increased risk of maternal hypotension. Clinically, the combination may result in diminished tocolytic response and potential cardiovascular instability."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYLTEZO vs DOXAZOSIN MESYLATE, answered by our medical review team.
CYLTEZO is a TNF-alpha Inhibitor that works by Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.. DOXAZOSIN MESYLATE is a Alpha-1 Blocker that works by Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYLTEZO and DOXAZOSIN MESYLATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYLTEZO is: Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.. The standard adult dose of DOXAZOSIN MESYLATE is: Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYLTEZO and DOXAZOSIN MESYLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYLTEZO is classified as Category C. CYLTEZO (adalimumab-adaz) is a TNF-alpha inhibitor. Human data on teratogenicity are limited; however, large cohort studies do not indicate a significant increase in major birth de. DOXAZOSIN MESYLATE is classified as Category A/B. FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.